Hess, G; Romaguera, J; Herbrecht, R et al.
TEMSIROLIMUS FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA: SUPPORTIVE EFFICACY ANALYSES FROM THE PHASE 3 STUDYHAEMATOLOGICA-THE HEMATOLOGY JOURNAL. Bd. 94. 2009 S. 391-392
Hess, G; Smith, SM; Berkenblit, A et al.
Temsirolimus in mantle cell lymphoma and other non-Hodgkin lymphoma subtypesSemin Oncol. Bd. S3. 2009 S. S37-45
Buske, C; Hoster, E; Dreyling, M et al.
The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG).Leukemia. Bd. 23. H. 1. 2009 S. 153-61
Jansen, NW; Roosendaal, G; Lundin, B et al.
The combination of the biomarkers urinary C-terminal telopeptide of type II collagen, serum cartilage oligomeric matrix protein, and serum chondroitin sulfate 846 reflects cartilage damage in hemophilic arthropathy.Arthritis Rheum. Bd. 60. H. 1. 2009 S. 290-8
Thaler, S; Schad, A; Steinmetz, I et al.
The interplay of RASSF1A and Akt1 in tumor invasion in a double-conditional xenograft modelEUROPEAN JOURNAL OF CELL BIOLOGY. Bd. 88. 2009 S. 10-10
Holgate, S; Buhl, R; Bousquet, J et al.
The use of omalizumab in the treatment of severe allergic asthma: A clinical experience update.Respir Med. Bd. 103. H. 8. 2009 S. 1098-113
Sieren, M; Buhl, R; Taube, C
Therapy of asthma bronchiale according to the guidelines - ReplyINTERNIST. Bd. 50. H. 4. 2009 S. 503-504
Schmidt, LH; Biesterfeld, S; Kümmel, A et al.
Tissue microarrays are reliable tools for the clinicopathological characterization of lung cancer tissueAnticancer Res. Bd. 29. 2009 S. 201-209
Bohme, A; Ruhnke, M; Buchheidt, D et al.
Treatment of invasive fungal infections in cancer patients--recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).Ann Hematol. Bd. 88. H. 2. 2009 S. 97-110
Sebastian, M; Kiewe, P; Schuette, W et al.
Treatment of Malignant Pleural Effusion With the Trifunctional Antibody Catumaxomab (Removab) (Anti-EpCAM x Anti-CD3) Results of a Phase 1/2 StudyJOURNAL OF IMMUNOTHERAPY. Bd. 32. H. 2. 2009 S. 195-202